Skip to main content
UniHealth

Doctor search

Bernice Y Kwong, MD

Dermatology · Stanford

NPI 1821275926

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
18
4 carriers
Offices
5

Offices

5 locations · Stanford Health Care · 3,152 clinicians in this group

Looking this up.

Hospitals listed: Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.

Plans that list them

18 plans · 4 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Kwong’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

18 of 18 plans

Plans whose provider directory lists this clinician
Alignment Health BreathEasy (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Clarity (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Harmony (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Honor+ Plan (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health My Choice CalCare (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Silicon (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health smartHMO (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health the ONE (HMO)Alignment Health PlanListedOct 3, 2026
Anthem Full Dual Advantage Aligned (HMO D-SNP)Anthem Blue CrossListedOct 3, 2026
SCAN Balance (HMO C-SNP)SCAN Health PlanListedOct 3, 2026
SCAN Classic (HMO)SCAN Health PlanListedOct 3, 2026
SCAN MyChoice (HMO)SCAN Health PlanListedOct 3, 2026
SCAN Strive (HMO C-SNP)SCAN Health PlanListedOct 3, 2026
DualConnect (HMO D-SNP)Santa Clara Family Health PlanListedSep 1, 2026

California Medical Board record

Licence A109243 · Current

Licensed to practise in California · since 2009 · expires 2027-05-31 · Yale University School of Medicine.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

Hospitals they work in

2 hospitals

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend it
    Overall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
  • Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend it
    Overall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths5.31 (4.24 to 6.37) · 8,661 casesWorseJul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits14.1 (12.7 to 15.7) · 2,191 casesWorseJan 2024 – Dec 2024
Postoperative respiratory failure rateComplications and deaths4.08 (1.95 to 6.21) · 5,296 casesBetterJul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.317BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.446BetterOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0.241BetterOct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.7 (0.6 to 0.9) · 3,348 casesBetterJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.06 (0.45 to 1.67) · 5,374 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.86 (0.72 to 1)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths166.09 (137.88 to 194.3) · 470 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.1 · 192 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths6.4 · 146 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths9.7 · 253 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths6.3 · 880 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 935 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths8.7 · 501 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.1 · 7,730 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.13 (0 to 0.27) · 20,799 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.28 (0.14 to 0.43) · 23,182 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths0.94 (0.2 to 1.68) · 5,694 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.36 (1.54 to 3.19) · 7,846 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.2 (3.76 to 6.64) · 5,603 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.38 (0.23 to 2.53) · 2,211 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.52 (0.21 to 0.83) · 19,915 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths3.6 · 416 casesNoneApr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.869No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.857No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0.368No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits16.2 · 247 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.5 · 1,021 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits47.8 · 258 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-1.6 · 990 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits20.8 · 976 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.5 · 959 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.2 (4.4 to 6.2) · 2,191 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.1 · 425 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits9.6 · 158 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.6 · 183 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.7 (10.4 to 15.4) · 4,578 casesNo differentJan 2022 – Dec 2024

What patients said (6,810 patients answered, 25% of those asked)

Patient survey stars by topic at Stanford Health Care
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness2
Recommend hospital5
Share of patients giving the best answer at Stanford Health Care
Room was "always" clean75%
Nurses "always" communicated well82%
Doctors "always" communicated well81%
Staff "always" explained63%
Yes, staff "did" give patients this information89%
Yes, staff "did" give patients information about help after discharge89%
Doctors "always" explained things so they could understand76%
Doctors "always" listened carefully80%
Doctors "always" treated them with courtesy and respect87%
Patients who gave a rating of "9" or "10" (high)79%
Staff "always" explained new medications76%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully79%
Nurses "always" treated them with courtesy and respect88%
"Always" quiet at night53%
"YES", patients would definitely recommend the hospital83%
Staff "always" explained possible side effects50%
Yes, staff "did" give patients information about possible symptoms90%
See every measure and the patient survey for Stanford Health Care Tri-Valley

Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care Tri-Valley
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.178BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.237BetterOct 2024 – Sep 2025
Abdominopelvic accidental puncture or laceration rateComplications and deaths0.79 (0 to 1.73) · 1,041 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.79 (0.5 to 1.08)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths145.81 (96.5 to 195.12) · 72 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths2.9 · 55 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths8.6 · 92 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths12.5 · 96 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths9.5 · 395 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 391 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths10.1 · 162 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths3 · 1,736 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.16 (0 to 0.37) · 4,425 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.22 (0.02 to 0.41) · 4,771 casesNo differentJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths3.45 (1.46 to 5.44) · 1,403 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths1.5 (0.05 to 2.94) · 645 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths1.81 (0.38 to 3.24) · 1,279 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths8.53 (3.2 to 13.85) · 639 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.15 (1.89 to 8.41) · 648 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.61 (0.14 to 3.07) · 370 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.16 (0 to 0.83) · 4,160 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths4 · 74 casesNoneApr 2023 – Mar 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.369No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections1.112No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits13.1 · 110 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.1 · 437 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits-5.8 · 94 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-19.3 · 456 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits-0.3 · 402 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits15.8 · 358 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits6.8 (4.7 to 9.6) · 198 casesNo differentJan 2024 – Dec 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits10.1 (7.5 to 13.6) · 198 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.3 · 80 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits10.9 · 46 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.3 · 92 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.4 (9.6 to 16.2) · 1,532 casesNo differentJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits1 (0.8 to 1.2) · 929 casesNo differentJan 2024 – Dec 2024

What patients said (1,268 patients answered, 26% of those asked)

Patient survey stars by topic at Stanford Health Care Tri-Valley
Cleanliness3
Nurse communication3
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating3
Quietness2
Recommend hospital4
Share of patients giving the best answer at Stanford Health Care Tri-Valley
Room was "always" clean65%
Nurses "always" communicated well77%
Doctors "always" communicated well79%
Staff "always" explained58%
Yes, staff "did" give patients this information88%
Yes, staff "did" give patients information about help after discharge88%
Doctors "always" explained things so they could understand74%
Doctors "always" listened carefully78%
Doctors "always" treated them with courtesy and respect86%
Patients who gave a rating of "9" or "10" (high)70%
Staff "always" explained new medications72%
Nurses "always" explained things so they could understand73%
Nurses "always" listened carefully74%
Nurses "always" treated them with courtesy and respect84%
"Always" quiet at night42%
"YES", patients would definitely recommend the hospital74%
Staff "always" explained possible side effects44%
Yes, staff "did" give patients information about possible symptoms89%

Original Medicare doctor bills

$169,114

Medicare paid this office $169,114 for 372 people. Most of that is long return visits and Botox.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Long return visit (40+ min)103$55,574$169
Long return visit (40+ min)139$46,635$128
New patient visit (60+ min)47$7,482$159
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes39$6,059$106
Destruction of skin growth, 1-14 growths54$5,258$65
See all 19 services
Every Original Medicare service billed
Long return visit (40+ min)103$55,574$169
Long return visit (40+ min)139$46,635$128
New patient visit (60+ min)47$7,482$159
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes39$6,059$106
Destruction of skin growth, 1-14 growths54$5,258$65
Return visit (30+ min)50$5,032$84
Destruction of precancer skin growth, 15 or more growths31$4,950$90
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's95$4,194$15
Initial hospital care with moderate level of medical decision making at least 75 minutes27$4,192$155
Telephone medical discussion with physician, 21-30 minutes19$3,416$118
Return visit (30+ min)22$3,414$118
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's84$2,741$15
Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or35$2,655$28
Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes86$2,648$30
Destruction of precancer skin growth, 1 growth45$2,570$42
Punch biopsy, first skin growth42$1,919$41
Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or20$1,426$30
Punch biopsy, each additional skin growth27$917$23
Destruction of precancer skin growth, 2-14 growths36$371$2

Procedures Medicare counted

Procedure volume Medicare published
Removal of skin lesions355More than 84% of doctors who do this
Removal of tissue1-10None
Removal or shaving of skin growth28More than 74% of doctors who do this
Skin biopsy100More than 76% of doctors who do this

Who their Medicare patients are

372 Original Medicare patients in 2024. Average age 73 · Under 65 10% · 85 and older 9% · Women 57% · Also on Medicaid 21% · Health risk score 2.98. Sicker patients than 9 in 10 peers; the typical dermatology clinician is at 1.01.

Conditions among them: High blood pressure 69% · Cancer 49% · Chronic kidney disease 31% · Diabetes 27% · Coronary heart disease 24% · Atrial fibrillation 22% · Heart failure 21% · Depression 21% · COPD 17% · Dementia 11% · Stroke 11%.

The office billed $746,765, Medicare allowed $216,388 and paid $169,114; for 2,234 services of 46 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
20243722,234732.98$746,765$169,114
20233691,508722.72$487,967$114,438
20223551,450722.76$460,063$98,553
20213811,604712.88$525,356$112,744
20203801,612722.86$508,245$104,508
20193371,813712.68$306,390$101,579
20184562,040702.67$296,729$112,264
20174111,838712.52$342,500$104,021
20164021,903702.41$354,702$105,362
20153471,576702.53$311,859$89,424
20143221,375702.26$293,458$83,238
2013224781702.14$166,203$48,227

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 17 services

Original Medicare services billed in 2023
Long return visit (40+ min)162$55,778$128
New patient visit (60+ min)70$11,184$160
Return visit (30+ min)82$10,574$89
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes41$6,472$108
Initial hospital care with moderate level of medical decision making at least 75 minutes29$4,798$160
Destruction of skin growth, 1-14 growths36$3,441$67
Destruction of precancer skin growth, 1 growth51$3,367$45
Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes77$2,592$32
Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or44$2,553$28
Destruction of precancer skin growth, 15 or more growths20$2,324$89
Punch biopsy, first skin growth43$1,916$42
Telephone medical discussion with physician, 21-30 minutes12$1,532$90
New patient visit (45+ min)12$1,473$123
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes11$1,315$120
Short return visit (20+ min)17$1,098$58
Punch biopsy, each additional skin growth29$877$24
Destruction of precancer skin growth, 2-14 growths41$517$2

2022: 17 services

Original Medicare services billed in 2022
Long return visit (40+ min)137$46,079$129
Return visit (30+ min)74$8,241$82
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes48$8,028$93
Initial hospital care with moderate level of medical decision making at least 75 minutes32$5,957$181
New patient visit (60+ min)35$5,830$167
Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or44$3,373$29
Destruction of precancer skin growth, 1 growth48$3,130$46
Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes80$2,724$32
Destruction of skin growth, 1-14 growths28$2,628$61
Punch biopsy, first skin growth50$2,174$42
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes15$1,869$125
Destruction of precancer skin growth, 15 or more growths13$1,322$88
Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes12$1,082$90
Punch biopsy, each additional skin growth34$973$24
Short return visit (20+ min)14$841$60
Destruction of precancer skin growth, 2-14 growths42$524$2
Biopsy of related skin growth, first growth17$420$22

2021: 17 services

Original Medicare services billed in 2021
Long return visit (40+ min)169$54,591$126
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes68$10,405$95
Return visit (30+ min)80$9,443$89
New patient visit (60+ min)39$6,298$161
Initial hospital care with moderate level of medical decision making at least 75 minutes32$6,153$186
Destruction of precancer skin growth, 1 growth51$3,819$47
Destruction of skin growth, 1-14 growths33$3,427$67
Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or45$3,180$30
Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes77$2,482$32
Punch biopsy, first skin growth52$2,412$43
Destruction of precancer skin growth, 15 or more growths19$2,036$85
Short return visit (20+ min)25$1,681$58
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes11$1,378$125
Punch biopsy, each additional skin growth33$1,043$24
Biopsy of related skin growth, first growth24$716$24
Destruction of precancer skin growth, 2-14 growths43$622$2
Biopsy of related skin growth, each additional growth11$312$21

2020: 17 services

Original Medicare services billed in 2020
Long return visit (40+ min)175$41,377$104
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes65$11,377$97
New patient visit (60+ min)70$10,641$152
Return visit (30+ min)95$10,195$72
Initial hospital care with moderate level of medical decision making at least 75 minutes30$5,845$189
Destruction of precancer skin growth, 1 growth62$3,588$44
New patient visit (45+ min)22$2,630$120
Destruction of skin growth, 1-14 growths28$2,477$67
Punch biopsy, first skin growth44$1,998$43
Long return visit (40+ min)15$1,749$109
Short return visit (20+ min)31$1,625$43
Destruction of precancer skin growth, 15 or more growths13$1,417$94
Punch biopsy, each additional skin growth37$1,354$25
Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes39$1,347$35
Return visit (30+ min)12$994$71
Destruction of precancer skin growth, 2-14 growths47$655$2
Biopsy of related skin growth, first growth23$591$25

2019: 15 services

Original Medicare services billed in 2019
Long return visit (40+ min)148$33,506$98
Return visit (30+ min)126$13,383$69
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes63$11,320$94
New patient visit (60+ min)59$8,986$152
Initial hospital care with moderate level of medical decision making at least 75 minutes28$5,323$184
Destruction of precancer skin growth, 1 growth79$5,156$43
New patient visit (45+ min)38$4,315$114
Destruction of skin growth, 1-14 growths43$3,885$65
Punch biopsy, first skin growth67$3,221$44
Short return visit (20+ min)41$2,387$42
Destruction of precancer skin growth, 15 or more growths20$2,293$88
Punch biopsy, each additional skin growth47$1,758$25
Biopsy of related skin growth, first growth33$1,063$30
Destruction of precancer skin growth, 2-14 growths62$977$2
Tissue fungi or parasites17$78$4

2018: 15 services

Original Medicare services billed in 2018
Long return visit (40+ min)198$37,251$97
Return visit (30+ min)148$15,067$67
New patient visit (60+ min)86$12,602$147
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes46$8,894$94
Initial hospital care with moderate level of medical decision making at least 75 minutes36$7,095$182
Biopsy of single growth of skin and/or tissue125$5,705$39
New patient visit (45+ min)50$5,410$108
Destruction of precancer skin growth, 1 growth78$5,288$42
Destruction of skin growth, 1-14 growths43$3,030$62
Biopsy of each additional growth of skin and/or tissue77$2,684$23
Short return visit (20+ min)42$2,212$44
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes13$1,589$122
Destruction of precancer skin growth, 2-14 growths65$1,070$2
New patient visit (30+ min)11$680$62
Tissue fungi or parasites19$79$4

2017: 15 services

Original Medicare services billed in 2017
Long return visit (40+ min)128$26,415$98
Return visit (30+ min)145$15,709$66
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes56$11,600$87
New patient visit (60+ min)67$9,565$143
Initial hospital care with moderate level of medical decision making at least 75 minutes41$8,006$178
New patient visit (45+ min)54$6,026$112
Biopsy of single growth of skin and/or tissue109$5,050$39
Destruction of precancer skin growth, 1 growth70$4,971$44
Destruction of skin growth, 1-14 growths33$3,171$66
Short return visit (20+ min)45$2,630$43
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes21$2,563$122
Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes22$1,974$90
Biopsy of each additional growth of skin and/or tissue59$1,863$22
Destruction of precancer skin growth, 2-14 growths58$936$2
Tissue fungi or parasites13$60$5

2016: 16 services

Original Medicare services billed in 2016
Long return visit (40+ min)138$25,314$97
Return visit (30+ min)145$18,202$68
New patient visit (60+ min)74$10,619$144
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes50$8,518$93
Biopsy of single growth of skin and/or tissue141$6,802$39
New patient visit (45+ min)55$6,321$115
Destruction of precancer skin growth, 1 growth79$6,247$49
Initial hospital care with moderate level of medical decision making at least 75 minutes32$6,129$180
Short return visit (20+ min)54$3,646$46
Biopsy of each additional growth of skin and/or tissue76$2,585$23
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes15$1,822$121
Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes17$1,606$89
Destruction of skin growth, 1-14 growths16$1,220$68
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes14$1,157$64
Destruction of precancer skin growth, 2-14 growths68$1,007$2
New patient visit (30+ min)13$783$60

2015: 16 services

Original Medicare services billed in 2015
Return visit (30+ min)140$18,067$69
Long return visit (40+ min)67$11,359$98
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes57$11,076$93
New patient visit (45+ min)79$9,011$114
Initial hospital care with moderate level of medical decision making at least 75 minutes38$7,060$181
Biopsy of single growth of skin and/or tissue120$5,515$38
New patient visit (60+ min)35$5,248$150
Destruction of precancer skin growth, 1 growth60$4,560$45
Short return visit (20+ min)45$3,229$44
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes23$2,929$122
Biopsy of each additional growth of skin and/or tissue73$2,507$23
Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes21$2,063$90
Destruction of skin growth, 1-14 growths19$1,595$61
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes17$1,230$65
New patient visit (30+ min)14$815$58
Destruction of precancer skin growth, 2-14 growths48$738$2

2014: 16 services

Original Medicare services billed in 2014
Return visit (30+ min)111$13,003$67
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes44$11,460$92
Long return visit (40+ min)66$10,934$97
New patient visit (60+ min)47$6,814$145
New patient visit (45+ min)55$6,109$111
Initial hospital care with moderate level of medical decision making at least 75 minutes28$5,216$180
Biopsy of single growth of skin and/or tissue106$5,144$41
Short return visit (20+ min)67$4,387$41
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes31$3,863$121
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes34$3,074$64
Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes30$2,678$89
Destruction of precancer skin growth, 1 growth46$2,597$41
Destruction of skin growth, 1-14 growths27$2,240$61
Biopsy of each additional growth of skin and/or tissue57$2,040$22
New patient visit (30+ min)28$1,807$65
Destruction of precancer skin growth, 2-14 growths28$433$2

2013: 14 services

Original Medicare services billed in 2013
Long return visit (40+ min)44$7,501$90
New patient visit (60+ min)51$7,191$141
Return visit (30+ min)58$5,431$65
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes31$4,960$90
Initial hospital care with moderate level of medical decision making at least 75 minutes24$4,829$172
Short return visit (20+ min)47$2,854$43
Biopsy of single growth of skin and/or tissue68$2,841$38
New patient visit (30+ min)34$2,070$61
New patient visit (45+ min)19$1,914$101
Destruction of precancer skin growth, 1 growth29$1,757$44
Destruction of skin growth, 1-14 growths22$1,740$58
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes13$1,548$119
Biopsy of each additional growth of skin and/or tissue35$911$22
Destruction of precancer skin growth, 2-14 growths19$490$4

Medicaid work

$11,897 in 2024

Medicaid paid $11,897 for 155 billed services this clinician did in 2024, up to 21 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Largest Medicaid services in 2024
Long return visit (40+ min)155$11,897
Medicaid work by year
2024155121$11,897
2023219223$14,919
202291118$5,831
202199116$4,602
202081119$2,696
201917114$684
See the largest Medicaid services in earlier years

2023

Largest Medicaid services in 2023
Long return visit (40+ min)206$14,516
SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES13$403

2022

Largest Medicaid services in 2022
Long return visit (40+ min)91$5,831

2021

Largest Medicaid services in 2021
Long return visit (40+ min)99$4,602

2020

Largest Medicaid services in 2020
Long return visit (40+ min)81$2,696

2019

Largest Medicaid services in 2019
Long return visit (40+ min)17$684

Drugs they prescribed that Part D paid

$256,232

Pharmacies billed $256,232 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 0% of their Part D prescriptions (0 of 675) in 2024. At or below the middle of the specialty; the typical dermatology clinician is at 0%.

615 generic and 60 brand-name prescriptions · $256,232 in drug cost · 52 antibiotic prescriptions to 29 people.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
Dupixent22$85,271$3,876
Opzelura15$37,557$2,504
Clobetasol Propionate56$3,375$60
Ivermectin13$1,252$96
Desoximetasone15$1,226$82
See all 19 drugs
Every Part D drug this clinician prescribed
Dupixent22$85,271$3,876
Opzelura15$37,557$2,504
Clobetasol Propionate56$3,375$60
Ivermectin13$1,252$96
Desoximetasone15$1,226$82
Ciclopirox26$949$37
Clotrimazole17$920$54
Triamcinolone Acetonide45$877$19
Fluocinonide24$792$33
Ketoconazole42$636$15
Doxycycline Monohydrate15$612$41
Mupirocin63$503$8
Ciclopirox33$482$15
Dexamethasone18$428$24
Hydroxyzine36$409$11
Nystatin17$271$16
Prednisone25$257$10
Hydrocortisone38$205$5
Cephalexin22$200$9

Year by year

Part D prescribing by year
20246751450% (0)9%$256,232
20236381470% (0)7%$123,068
20224471150% (0)None$44,609
20214811360% (0)3%$27,814
20205771930% (0)8%$48,882
20197031910% (0)12%$70,503
20188582430% (0)16%$137,872
20175351570% (0)12%$79,931
2016495165NoneNone$71,634
2015402127None12%$51,064
2014328121None13%$27,962
2013185810% (0)14%$13,547

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 22 drugs

Part D drugs prescribed in 2023
Opzelura18$60,405$3,356
Clobetasol Propionate74$5,492$74
Tacrolimus13$2,395$184
Ciclopirox37$2,125$57
Betamethasone Dipropionate16$1,859$116
Desoximetasone14$1,803$129
Triamcinolone Acetonide53$1,342$25
Ciclopirox26$1,081$42
Doxycycline Monohydrate18$1,077$60
Ketoconazole39$1,060$27
Fluocinolone Acetonide16$998$62
Gentamicin Sulfate12$937$78
Mupirocin46$589$13
Hydroxyzine28$577$21
Clotrimazole11$559$51
Hydrocortisone48$527$11
Dexamethasone12$520$43
Fluocinonide12$519$43
Valacyclovir13$447$34
Nystatin20$357$18
Cephalexin19$240$13
Prednisone24$226$9

2022: 13 drugs

Part D drugs prescribed in 2022
Clobetasol Propionate44$2,439$55
Triamcinolone Acetonide50$2,313$46
Tacrolimus12$1,891$158
Ciclopirox27$1,421$53
Betamethasone Dipropionate12$1,038$86
Mupirocin50$644$13
Ketoconazole31$635$20
Prednisone25$564$23
Doxycycline Monohydrate13$524$40
Dexamethasone13$373$29
Nystatin12$369$31
Cephalexin12$260$22
Hydrocortisone27$252$9

2021: 12 drugs

Part D drugs prescribed in 2021
Clobetasol Propionate42$3,565$85
Tacrolimus22$3,418$155
Triamcinolone Acetonide40$1,566$39
Ciclopirox21$1,305$62
Valacyclovir28$907$32
Mupirocin68$901$13
Ketoconazole26$745$29
Doxycycline Monohydrate19$594$31
Ciclopirox21$534$25
Hydrocortisone42$399$10
Hydroxyzine16$328$21
Cephalexin13$150$12

2020: 16 drugs

Part D drugs prescribed in 2020
Tacrolimus19$8,365$440
Clobetasol Propionate40$6,247$156
Betamethasone Dipropionate33$5,135$156
Triamcinolone Acetonide90$2,555$28
Ivermectin17$2,116$124
Clotrimazole16$1,955$122
Doxycycline Hyclate23$1,342$58
Fluocinonide17$1,255$74
Valacyclovir26$1,175$45
Mupirocin73$781$11
Ketoconazole29$517$18
Dexamethasone15$514$34
Hydrocortisone43$388$9
Cephalexin22$313$14
Ciclopirox15$284$19
Prednisone14$124$9

2019: 18 drugs

Part D drugs prescribed in 2019
Tacrolimus19$12,567$661
Clobetasol Propionate50$8,787$176
Soolantra11$7,063$642
Betamethasone Dipropionate44$7,007$159
Triamcinolone Acetonide103$2,538$25
Fluocinonide25$2,347$94
Doxycycline Hyclate31$2,127$69
Ketoconazole54$1,983$37
Metronidazole17$1,759$103
Valacyclovir26$1,650$63
Mupirocin80$1,463$18
Permethrin12$1,111$93
Ciclopirox23$689$30
Hydrocortisone63$632$10
Nystatin13$358$28
Cephalexin18$298$17
Gabapentin15$257$17
Prednisone12$116$10

2018: 20 drugs

Part D drugs prescribed in 2018
Tacrolimus29$19,858$685
Doxepin21$15,076$718
Betamethasone Dipropionate64$12,250$191
Metronidazole15$11,534$769
Fluocinonide52$6,395$123
Triamcinolone Acetonide156$3,904$25
Betamethasone Diprop Augmented15$2,510$167
Clobetasol Propionate14$2,438$174
Fluocinolone Acetonide13$1,978$152
Mupirocin91$1,641$18
Ketoconazole55$1,599$29
Valacyclovir23$1,218$53
Doxycycline Hyclate16$1,031$64
Ciclopirox22$1,012$46
Clotrimazole11$906$82
Hydroxyzine25$864$35
Clindamycin Phosphate12$727$61
Hydrocortisone76$718$9
Cephalexin27$364$13
Prednisone11$141$13

2017: 12 drugs

Part D drugs prescribed in 2017
Tacrolimus14$9,792$699
Clobetasol Propionate24$4,521$188
Fluocinonide35$3,654$104
Fluocinolone Acetonide13$2,084$160
Triamcinolone Acetonide90$2,056$23
Metronidazole15$1,436$96
Ketoconazole34$1,276$38
Mupirocin51$712$14
Cephalexin41$526$13
Ciclopirox20$512$26
Hydroxyzine11$336$31
Hydrocortisone44$274$6

2016: 13 drugs

Part D drugs prescribed in 2016
Tacrolimus22$9,912$451
Clobetasol Propionate37$7,897$213
Desonide16$2,987$187
Fluocinonide22$2,658$121
Triamcinolone Acetonide82$2,577$31
Econazole Nitrate20$2,550$128
Ketoconazole28$844$30
Ciclopirox12$380$32
Valacyclovir12$374$31
Mupirocin23$284$12
Hydrocortisone29$281$10
Sulfamethoxazole-Trimethoprim12$196$16
Cephalexin21$190$9

2015: 12 drugs

Part D drugs prescribed in 2015
Clobetasol Propionate32$10,653$333
Tacrolimus14$4,771$341
Fluocinonide20$2,071$104
Econazole Nitrate12$1,896$158
Doxycycline Hyclate13$1,844$142
Desonide15$1,679$112
Triamcinolone Acetonide66$1,422$22
Ketoconazole40$806$20
Mupirocin27$360$13
Hydroxyzine15$312$21
Hydrocortisone18$280$16
Cephalexin20$231$12

2014: 7 drugs

Part D drugs prescribed in 2014
Clobetasol Propionate26$3,115$120
Triamcinolone Acetonide61$2,666$44
Fluocinonide13$685$53
Mupirocin29$455$16
Ketoconazole18$278$15
Hydrocortisone11$270$25
Cephalexin24$252$11

2013: 6 drugs

Part D drugs prescribed in 2013
Desonide14$2,448$175
Clobetasol Propionate35$2,020$58
Fluocinonide19$1,467$77
Triamcinolone Acetonide30$1,181$39
Ketoconazole14$307$22
Hydrocortisone12$74$6

Money from drug and device companies

$3,440 in 2025

Industry payments by year
202522$3,440$3,440
202445$10,596$10,596
202212$4,560$4,560
202111$2,640$2,640
201917$6,300$7,628

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
Janssen Scientific AffairsRybrevant$2,700
1 payment
  • Consulting for Rybrevant · 2025-03-31 · $2,700
Janssen Global ServicesNone$740
1 payment
  • Consulting · 2025-02-28 · $740
See all 2 published payments
Every published payment
Janssen Scientific AffairsConsulting · 2025-03-31Rybrevant$2,700
Janssen Global ServicesConsulting · 2025-02-28None$740
See earlier years (2024, 2022, 2021, 2019)

2024: $10,596

Payments by company in 2024
Janssen Scientific AffairsNone$3,630
2 payments
  • Consulting · 2024-11-04 · $1,210
  • Consulting · 2024-09-20 · $2,420
GenzymeDupixent$3,226
1 payment
  • Consulting for Dupixent · 2024-06-06 · $3,226
NovocureNone$3,000
1 payment
  • Honoraria · 2024-03-14 · $3,000
Janssen Global ServicesNone$740
1 payment
  • Consulting · 2024-11-04 · $740

2022: $4,560

Payments by company in 2022
Novartis PharmaceuticalsPiqray$4,560
2 payments
  • Consulting for Piqray · 2022-06-10 · $960
  • Consulting for Piqray · 2022-03-30 · $3,600

2021: $2,640

Payments by company in 2021
Novartis PharmaceuticalsPiqray$2,640
1 payment
  • Consulting for Piqray · 2021-12-31 · $2,640

2019: $7,628

Payments by company in 2019
Kyowa KirinPoteligeo$7,628
7 payments
  • Travel for Poteligeo · 2019-11-02 · $119
  • Travel for Poteligeo · 2019-11-02 · $837
  • Travel for Poteligeo · 2019-11-02 · $229
  • Meals for Poteligeo · 2019-11-02 · $48
  • Meals for Poteligeo · 2019-11-02 · $45
  • Consulting for Poteligeo · 2019-11-02 · $6,300
  • Meals for Poteligeo · 2019-11-02 · $50

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
Novartis Pharmaceuticals Corporation · Expert Consensus Recommendations for Managing Hyperglycemia and Rash Associated With Alpelisib-Breast Cancer Res Treat · 2023This clinician$6,154
NOVARTIS PHARMACEUTICALS CORPORATION · Publication Support Provided in Connection With Heor Research · 2022This clinician$619
Novartis Pharmaceuticals Corporation · Byl-Ab -117225-Expert Consensus Recommendations for Managing Hyperglycemia and Rash in Patients With Pik3ca-Mutated, Hormone Receptor-Positive (Hr+), Human Epidermal Growth Factor Receptor 2-Negative (Her2?) Advanced Breast Cancer (Abc) Treated With Alp · 2023This clinician$509

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
76.5 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI
1821275926
Licence
CA A109243California A109243: Current · expires 2027-05-31
Trained
Yale University School of Medicine, 2007
Video visits
Lists video visits
Gender
Female
More record details
Sole proprietor
Yes
Taxonomy
Federal specialty code 207N00000X (207N00000X)
Mailing address
300 Pasteur Dr, Stanford, CA, 94305
NPI first listed
2008-01-31
NPI last updated
2024-04-16
NPI record certified
2024-04-16

This is when the NPI record was last certified, not a medical board exam.